Evaluation and Management of Burning Mouth Syndrome in Cardiac Patients
First, systematically exclude secondary causes through targeted investigations, then provide reassurance that the condition will not worsen, followed by cognitive behavioral therapy as first-line management, with topical clonazepam or neuropathic pain medications reserved for refractory cases.
Initial Diagnostic Approach
Rule Out Secondary Causes First
The critical first step is excluding all treatable secondary causes before diagnosing primary BMS 1. This is essential because secondary causes include:
- Oral candidiasis (most commonly misdiagnosed condition—25.5% of cases) 1, 2
- Hematological disorders (nutritional deficiencies, anemia) 1, 3
- Autoimmune disorders 1
- Medication side effects 1, 4
- Mucosal lesions 1
Specific Cardiac Patient Considerations
In cardiac patients, carefully review their medication list for potential drug-induced causes 4. One case report documented BMS induced by empagliflozin (SGLT2 inhibitor), which resolved upon drug withdrawal 4. Other cardiac medications may similarly contribute to oral burning sensations.
Key History Elements
Document these specific characteristics 1:
- Location: Bilateral tongue tip, lips, palate, or buccal mucosa (most commonly tongue) 1
- Timing: Continuous burning that typically worsens throughout the day and peaks in evening/night 5
- Quality: Burning, stinging, or itchy sensation 1
- Associated symptoms: Dry mouth, abnormal taste, depression, poor quality of life 1
- Aggravating/relieving factors: Sometimes eating aggravates, in others it relieves symptoms 1
Physical Examination
The oral mucosa appears completely normal on examination—this is pathognomonic for primary BMS 1. Any visible lesions suggest an alternative diagnosis.
Diagnostic Workup
Order targeted laboratory tests to exclude secondary causes 3:
- Complete blood count (anemia, nutritional deficiencies)
- Fasting glucose (diabetes mellitus)
- Nutritional panels (B vitamins, iron, folate)
- Consider thyroid function if clinically indicated
No imaging or specialized testing is required for primary BMS 1. The diagnosis is clinical after exclusion of secondary causes.
Management Strategy
Essential First Step: Reassurance
Provide explicit reassurance that BMS will not worsen over time—this is often crucial for patient coping 1. While the prognosis shows only a small number resolve fully, patients need to understand the condition is stable and not progressive 1.
First-Line Treatment: Cognitive Behavioral Therapy
Cognitive behavioral therapy (CBT) demonstrates favorable outcomes in both short-term and long-term assessment 1, 6. The British Journal of Anaesthesia guidelines specifically recommend CBT as primary management 1.
Pharmacological Options for Refractory Cases
When CBT alone is insufficient, consider these evidence-based options:
Topical Clonazepam (Preferred Topical Agent)
Topical clonazepam shows favorable outcomes in both short- and long-term assessment 6. This is recommended for peripheral-origin BMS 5.
Systemic Neuropathic Pain Medications
For central-type BMS, consider 5:
- Duloxetine (antidepressant with neuropathic pain efficacy)
- Gabapentin (anticonvulsant)
- Amisulpride (dopaminergic agent)
Topical Capsaicin
Topical capsaicin demonstrates favorable outcomes in both short- and long-term assessment 6.
Alpha-Lipoic Acid
Alpha-lipoic acid shows low initial benefit but positive effects increase with long-term assessment 6. Some evidence suggests combining it with gabapentin may be beneficial 1.
Low-Level Laser Therapy
Laser therapy demonstrates favorable outcomes in both short- and long-term assessment 6.
Treatment Approach Limitations
Be aware that RCTs for BMS are often of poor quality, and there is a high percentage of treatment failures 1. An open-label study of amitriptyline showed some benefit, but an RCT of Botulinum Toxin showed no benefit 1.
Common Pitfalls to Avoid
Misdiagnosis as Candidiasis
Candidiasis is the most common misdiagnosis (25.5% of cases), leading to inappropriate antifungal treatment (27.5% of patients) 2. Do not prescribe antifungals without visible lesions or positive cultures.
Delayed Diagnosis
Median time from symptom onset to correct diagnosis is 12 months, with patients seeing a median of 3 providers 2. Recognize BMS early to prevent unnecessary testing and inappropriate treatments.
Unnecessary Testing
30.4% of patients undergo unnecessary diagnostic tests before correct diagnosis 2. After excluding secondary causes with basic labs, additional testing is not indicated.
Overlooking Drug-Induced Causes
In cardiac patients specifically, review and consider trial withdrawal of potentially causative medications 4, particularly newer agents like SGLT2 inhibitors.
Prognosis and Follow-Up
BMS is a chronic condition with poor prognosis for complete resolution, but it remains stable and does not progress 1. The condition represents a disorder of peripheral nerve fibers with central brain changes, supported by neurophysiological testing, biopsies, and functional MRI 1.
Patients often have comorbid depression and other chronic pain conditions requiring a biopsychosocial approach 1, 7. Address these comorbidities as part of comprehensive management.